Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...

Sorriso Pharmaceuticals presents Phase 1b data for SOR102, an oral bispecific antibody for IBD, showing 40% endoscopic ...

AstraZeneca reports positive interim results for camizestrant in Phase 3 SERENA-6 trial, showing PFS benefit in ER-positive ...

Medicare use of GLP-1 diabetes drugs like Ozempic rose 900% over 5 years, with 2023 spending at $35.8B. HHS report shows ...

Regeneron is now expecting an accelerated approval decision this summer on its T cell engager for one form of lymphoma, while ...

Eli Lilly is continuing to invest big in US pharma manufacturing, with the addition of three new domestic API sites and ...

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...

Several small clinical trials have demonstrated that gene therapies have restored hearing in children with a rare form of genetic deafness.

Harbour BioMed's subsidiary inks $395M deal, ORIC plans Phase 3 trials, Idorsia updates on deals, Sanofi backs Enveda, Zymeworks gets GSK milestone, BerGenBio ends study, Ignota raises £5.5M ...

Ginkgo Bioworks’ stock $DNA fell by around 13% premarket Wednesday after the company dampened its 2025 sales forecast.

Merck warns Keytruda faces IRA price cuts from 2028, alongside patent expiry and biosimilar competition. Drug hit $29.5B ...

To Candel Therapeutics CEO Paul Peter Tak, the biotech’s viral immunotherapy has passed the 'bloody obvious test' in ...